Have a feature idea you'd love to see implemented?
Let us know!
LFCR Lifecore Biomedical Inc
Price (delayed)
$6.99
Market cap
$215.98M
P/E Ratio
31.77
Dividend/share
N/A
EPS
$0.22
Enterprise value
$347.32M
Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for
Highlights
Lifecore Biomedical's gross profit has surged by 80% YoY and by 6% QoQ
The company's gross margin rose by 46% YoY and by 6% QoQ
LFCR's equity has dropped by 135% since the previous quarter but it has surged by 71% year-on-year
LFCR's EPS has soared by 107% YoY but it is down by 45% QoQ
The company's quick ratio fell by 25% QoQ and by 24% YoY
Lifecore Biomedical's debt has increased by 15% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of LFCR
Market
Valuations
Earnings
Shares outstanding
30.9M
Market cap
$215.98M
Enterprise value
$347.32M
Price to earnings (P/E)
31.77
Price to book (P/B)
N/A
Price to sales (P/S)
1.68
EV/EBIT
13.29
EV/EBITDA
9.98
EV/Sales
2.7
Revenue
$128.45M
EBIT
$26.13M
EBITDA
$34.81M
Free cash flow
-$8.79M
Per share
Balance sheet
Liquidity
EPS
$0.22
Free cash flow per share
-$0.28
Book value per share
-$0.13
Revenue per share
$4.16
TBVPS
$7.41
Total assets
$246.82M
Total liabilities
$207.32M
Debt
$136.86M
Equity
-$3.94M
Working capital
$33.66M
Debt to equity
-34.75
Current ratio
1.83
Quick ratio
0.76
Net debt/EBITDA
3.77
Margins
Efficiency
Dividend
EBITDA margin
27.1%
Gross margin
34.7%
Net margin
5.1%
Operating margin
-9.2%
Return on assets
2.6%
Return on equity
98.7%
Return on invested capital
8.3%
Return on capital employed
12.7%
Return on sales
20.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LFCR stock price
How has the Lifecore Biomedical stock price performed over time
Intraday
-6.55%
1 week
4.64%
1 month
33.14%
1 year
-5.92%
YTD
12.92%
QTD
41.78%
Financial performance
How have Lifecore Biomedical's revenue and profit performed over time
Revenue
$128.45M
Gross profit
$44.51M
Operating income
-$11.81M
Net income
$6.54M
Gross margin
34.7%
Net margin
5.1%
Lifecore Biomedical's net income has soared by 107% YoY but it has decreased by 46% from the previous quarter
Lifecore Biomedical's net margin has soared by 105% YoY but it has decreased by 46% from the previous quarter
Lifecore Biomedical's gross profit has surged by 80% YoY and by 6% QoQ
LFCR's operating margin has soared by 65% YoY but it is down by 33% from the previous quarter
Growth
What is Lifecore Biomedical's growth rate over time
Valuation
What is Lifecore Biomedical stock price valuation
P/E
31.77
P/B
N/A
P/S
1.68
EV/EBIT
13.29
EV/EBITDA
9.98
EV/Sales
2.7
LFCR's EPS has soared by 107% YoY but it is down by 45% QoQ
LFCR's equity has dropped by 135% since the previous quarter but it has surged by 71% year-on-year
The price to sales (P/S) is 25% lower than the 5-year quarterly average of 2.4 but 6% higher than the last 4 quarters average of 1.7
LFCR's revenue is up by 23% YoY
Efficiency
How efficient is Lifecore Biomedical business performance
Lifecore Biomedical's return on invested capital has surged by 129% YoY but it has decreased by 15% QoQ
LFCR's ROS has soared by 126% YoY but it is down by 14% QoQ
Lifecore Biomedical's ROE has soared by 122% YoY but it has plunged by 65% from the previous quarter
The ROA has soared by 107% YoY but it has contracted by 46% from the previous quarter
Dividends
What is LFCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LFCR.
Financial health
How did Lifecore Biomedical financials performed over time
LFCR's total assets is 19% more than its total liabilities
The company's quick ratio fell by 25% QoQ and by 24% YoY
The company's current ratio fell by 22% YoY and by 12% QoQ
LFCR's equity has dropped by 135% since the previous quarter but it has surged by 71% year-on-year
Lifecore Biomedical's debt has increased by 15% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.